You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
Moodys
Harvard Business School
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,345,767

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,345,767
Title:Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor
Abstract: A method for predicting a therapeutic effect of chemotherapy with a combination drug containing tegafur, gimeracil, and oteracil potassium in a gastric cancer patient by: (1) measuring an expression level of epidermal growth factor receptor (EGFR) in a biological sample obtained from the patient; (2) comparing the expression level of EGFR obtained in step (1) with a corresponding predetermined cut-off point; and (3) predicting that the patient is likely to sufficiently respond to chemotherapy when a tegafur, gimeracil, and oteracil potassium combination drug is used with an EGFR inhibitor, when the step (2) comparison reveals that the expression level of EGFR is greater than the cut-off point, or predicting that the patient is likely to sufficiently respond to chemotherapy when a tegafur, gimeracil, and oteracil potassium combination drug is used alone, when the step (2) comparison reveals that the expression level of EGFR is not greater than the cut-off point.
Inventor(s): Kobunai; Takashi (Tokyo, JP), Saito; Hitoshi (Tokushima, JP), Takechi; Teiji (Tokyo, JP)
Assignee: TAIHO PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:14/117,426
Patent Claims:see list of patent claims

Details for Patent 9,345,767

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Tokyo, JP) 2031-05-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
Harvard Business School
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.